ALYACEN 1/35 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Alyacen 1/35, and what generic alternatives are available?
Alyacen 1/35 is a drug marketed by Glenmark Generics and is included in one NDA.
The generic ingredient in ALYACEN 1/35 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
Summary for ALYACEN 1/35
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 7 |
Patent Applications: | 166 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ALYACEN 1/35 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ALYACEN 1/35
US Patents and Regulatory Information for ALYACEN 1/35
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glenmark Generics | ALYACEN 1/35 | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 091634-001 | Jan 19, 2012 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |